Navigation Links
Update on the SEAS Study
Date:7/21/2008

LONDON, July 21 /PRNewswire/ -- Professor Terje Pedersen (Ulleval University Hospital, Oslo, Norway), lead investigator for the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) Study, will provide an update on the study on Monday the 21st July.

Also present in London will be Sir Richard Peto (Professor of Medical Statistics and Epidemiology and Co-director of the Clinical Trials Service Unit, University of Oxford) Professor Rory Collins (BHF Professor of Medicine and Epidemiology at the University of Oxford and Co-director of the Clinical Trials Service Unit) and Professor Ingar Holme, PhD, (Professor of Biostatistics, University of Oslo and Ulleval University Hospital, Oslo, Norway), SEAS steering committee statistician.

The London panel will be joined by Professor Eugene Braunwald (Professor of Medicine at Harvard Medical School) who will participate via Web link from Boston and Professor Robert M Califf (Professor of Medicine, Head of Duke Clinical Research, Duke University) available via phone link.
You are invited to join us at:

The Hilton London Metropole Hotel,

King Suite (3rd Floor, West Wing),

225 Edgware Road, London W2 1JU

When: 21st July at 5.30pm for a 6pm start, BST

OR

The press conference will be Webcast live, and archived, available at:

http://clients.mediaondemand.net/pedersen/live.asx

http://clients.mediaondemand.net/pedersen/archive.asx Additionally the press conference can be accessed via satellite and full coordinates for USA and Europe will be issued by 1pm BST.

There will be a Q&A session after the press announcement. The Q&A session is only available for members of the media.


'/>"/>
SOURCE ;
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. FDA Updates Label for AVANDIA(R) to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years
2. Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
3. IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP)
4. SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
5. ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
6. Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
7. GSK Update on FDA Review of Promacta(R) (Eltrombopag)
8. XTENT Announces European Regulatory Update
9. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
10. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
11. Genmab Announces Updates on Phase III Cancer Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... financial results for the first quarter 2017 after the ... Company,s management team will host a corresponding conference call ... Investors interested in listening to the conference ... domestic callers or (703) 326-3030 for international callers, using ...
(Date:4/19/2017)... April 19, 2017 Global Prostate Cancer ... on the prostate cancer therapeutics market analyzes the ... Increasing prevalence of prostate cancer, launch of promising ... development of new drugs & therapeutic biological products, ... due to lesser side effects are some of ...
(Date:4/19/2017)... -- The Global Effective Microorganisms (EM) Market by ... covered and analysed the potential of Global Effective Microorganisms (EM) ... and growth factors. The report identifies and analyses the emerging ... global market. ... Tables and Figures, 6 Major Company Profiles, spread across 124 ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... 2017 , ... Accreditation Commission for Health Care (ACHC) is ... (HCAOA). This agreement allows HCAOA members to receive special pricing on ACHC’s Home ... University (AU) educational resources that help prepare HCAOA members for ACHC Accreditation. , ...
(Date:4/28/2017)... ... ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced today that ... as “stable.” At the same time, the ratings agency cautioned that the company’s rating ... “capital adequacy” thresholds required for its strong rating. , “Horizon is committed to being ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... tubes . These lamps offer an instant energy-saving solution for F32T8 fluorescent lamps ... fixtures or disconnect ballasts. These 50,000 hour rated lamps utilize the existing electronic ...
(Date:4/28/2017)... ... ... The Texas Cord Blood Bank (TCBB), a program of nonprofit biomedical organization GenCure, ... at Renaissance in Edinburg for their outstanding efforts in collecting umbilical cord blood donations ... , “Women’s Hospital at Renaissance has been a collection partner for the TCBB since ...
(Date:4/28/2017)... Ca (PRWEB) , ... April 28, 2017 , ... Bill ... management industry in the coastal communities. After Tina Howe joined the team, the Bill ... happy employees, honest services at affordable rates, and giving back to the San Diego ...
Breaking Medicine News(10 mins):